CA2624693A1 - Methodes et compositions pharmaceutiques comprenant des acides carboxyalkylsulfoniques - Google Patents

Methodes et compositions pharmaceutiques comprenant des acides carboxyalkylsulfoniques Download PDF

Info

Publication number
CA2624693A1
CA2624693A1 CA002624693A CA2624693A CA2624693A1 CA 2624693 A1 CA2624693 A1 CA 2624693A1 CA 002624693 A CA002624693 A CA 002624693A CA 2624693 A CA2624693 A CA 2624693A CA 2624693 A1 CA2624693 A1 CA 2624693A1
Authority
CA
Canada
Prior art keywords
subject
disease
amyloid
compound
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002624693A
Other languages
English (en)
Inventor
Xianqi Kong
Julie Laurin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bellus Health International Ltd
Original Assignee
Neurochem (International) Limited
Xianqi Kong
Julie Laurin
Bellus Health (International) Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurochem (International) Limited, Xianqi Kong, Julie Laurin, Bellus Health (International) Limited filed Critical Neurochem (International) Limited
Publication of CA2624693A1 publication Critical patent/CA2624693A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA002624693A 2005-09-30 2006-10-02 Methodes et compositions pharmaceutiques comprenant des acides carboxyalkylsulfoniques Abandoned CA2624693A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US72289105P 2005-09-30 2005-09-30
US60/722,891 2005-09-30
PCT/IB2006/004011 WO2007063428A2 (fr) 2005-09-30 2006-10-02 Méthodes et compositions pharmaceutiques comprenant des acides carboxyalkylsulfoniques

Publications (1)

Publication Number Publication Date
CA2624693A1 true CA2624693A1 (fr) 2007-06-07

Family

ID=38092635

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002624693A Abandoned CA2624693A1 (fr) 2005-09-30 2006-10-02 Methodes et compositions pharmaceutiques comprenant des acides carboxyalkylsulfoniques

Country Status (5)

Country Link
EP (1) EP1937239A2 (fr)
JP (1) JP2009510050A (fr)
AU (1) AU2006321294A1 (fr)
CA (1) CA2624693A1 (fr)
WO (1) WO2007063428A2 (fr)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840294A (en) * 1993-03-29 1998-11-24 Queen's University At Kingston Method for treating amyloidosis
JP2002020393A (ja) * 2000-06-30 2002-01-23 Sumitomo Pharmaceut Co Ltd スルホン酸誘導体
MXPA05013692A (es) * 2003-06-23 2006-03-13 Neurochem Int Ltd Metodos para tratar trastornos por acumulacion de proteina.
MXPA05013977A (es) * 2003-06-23 2006-03-09 Neurochem Int Ltd Metodos y composiciones para tratar enfermedades relacionadas con amiloide.

Also Published As

Publication number Publication date
WO2007063428A2 (fr) 2007-06-07
EP1937239A2 (fr) 2008-07-02
AU2006321294A1 (en) 2007-06-07
JP2009510050A (ja) 2009-03-12
WO2007063428A3 (fr) 2008-01-17

Similar Documents

Publication Publication Date Title
RU2361862C2 (ru) Пиррольные и пиразольные ингибиторы daao
US9636316B2 (en) Baclofen and acamprosate based therapy of neurological disorders
Cheng et al. Retinoic acid protects against proteasome inhibition associated cell death in SH-SY5Y cells via the AKT pathway
US7166725B2 (en) Benzo[d]isoxazol-3-ol DAAO inhibitors
US20030162825A1 (en) D-amino acid oxidase inhibitors for learning and memory
US20060167057A1 (en) Compounds for the treatment of CNS and amyloid associated diseases
CA3032609A1 (fr) Composes de piegeage d'aldehydes et leurs procedes d'utilisation
EP2809318B1 (fr) Dérivés d'acide sulfonique, d'acide phosphonique et d'acide carboxylique, contenant de l'ammonium, et leur utilisation médicale
JP2010535783A (ja) 縮合複素環
Suresh et al. Pharmacological tools to modulate autophagy in neurodegenerative diseases
CN108026049A (zh) 用于治疗和预防神经退化性病症的组合物和方法
DE69933885T2 (de) Triphenylbutenderivate zur behandlung von neurologischen störungen
JP2023153894A (ja) ８－ヒドロキシキノリン誘導体のエナンチオマーの合成
CA2624693A1 (fr) Methodes et compositions pharmaceutiques comprenant des acides carboxyalkylsulfoniques
EP2002863A1 (fr) Dérivés de phénanthroline [1,10] pour le traitement de maladies neurodégénératives ou hématologiques
JP2021520413A (ja) 眼科的状態のための療法
CA2528627A1 (fr) Methods for treating protein aggregation disorders
Lu et al. Caspase-mediated suppression of glutamate (AMPA) receptor channel activity in hippocampal neurons in response to DNA damage promotes apoptosis and prevents necrosis: implications for neurological side effects of cancer therapy and neurodegenerative disorders
EP1977748A1 (fr) Composes a proprietes neuroprotectrices
WO2007023389A2 (fr) Formes polymorphes de l'acide 3-amino-1-propanesulfonique
JP2024038270A (ja) パーキンソン病およびその他の神経変性疾患を処置するためのルビジウムおよび／または亜鉛化合物
Voronkov et al. Effect of pumpkin (Cucurbita pepo L.) and marigold (Tagetes Patula L.) Extracts on hippocampal mitochondria functional activity within conditions of experimental acute brain hypometabolism
US20240189312A1 (en) Composition for treating acute brain injury or neurodegenerative disease, method of making, and use thereof
JP2007526228A (ja) アミロイド関連疾患およびてんかん発生関連疾患の治療のための方法および組成物
KR20210135089A (ko) 1,5-디카페오일퀴닉산 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 시뉴클레인병증의 예방 또는 치료용 조성물

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead